Company profile: ALK
1.1 - Company Overview
Company description
- Provider of allergy treatments, vaccination, and immunotherapy, offering SLIT tablets and drops for common respiratory allergies (house dust mite, grass, birch-family trees, ragweed, Japanese cedar), immunotherapy that addresses underlying causes and allergic asthma, a web shop and klarify.me with drug-free products/services, and a developing peanut allergy tablet.
Products and services
- Allergy immunotherapy: Immune-reprogramming-based treatments that address the underlying cause of respiratory allergies and allergic asthma by reprogramming the immune system to better handle specific allergens
- SLIT-tablets: Sublingual-format immunotherapy tablets that treat respiratory allergies to house dust mite, grass, birch-family trees, ragweed, and Japanese cedar by targeting specific allergen sensitivities
- SLIT-drops: Oral sublingual immunotherapy drops that treat various allergies by administering allergen extracts under the tongue to help people manage allergy symptoms and address allergen-specific sensitivities
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ALK
Nautilus Biotechnology
HQ: United States
Website
- Description: Provider of a high-throughput, low-cost proteome analysis platform enabling single-molecule protein counting and comprehensive quantification across the human proteome. Offers the Nautilus Proteome Analysis Platform, the PrISM theoretical framework, and multi-affinity probes to analyze up to 10 billion protein molecules per run with an expected dynamic range spanning up to 9 orders of magnitude.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nautilus Biotechnology company profile →
Polyplus Transfection
HQ: France
Website
- Description: Provider of innovative solutions for in vivo, in vitro and ex vivo delivery of nucleic acids for research, bioproduction and therapeutics, including transfection reagents for lentiviral (FectoVIR®-LV) and AAV production (FectoVIR®-AAV), PEIpro® for viral vector bioproduction, in vivo–jetPEI®, LipidBrick® Library for LNP formulation, and in vivo-jetRNA®+ for mRNA/saRNA delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Polyplus Transfection company profile →
DNA Genotek
HQ: Canada
Website
- Description: Provider of biological sample collection, stabilization, and preparation products for health research institutes, offering human and animal DNA/RNA collection kits, stabilization and preparation reagents, and self-collection devices for saliva, oral microbiome, and first-void urine (OMNIgene, ORAcollect, Colli-Pee), plus prepIT kits and reagents for DNA extraction and inhibitor removal for downstream assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNA Genotek company profile →
Noroit
HQ: France
Website
- Description: Provider of protective equipment against biological risks, including airflow cabinets and modules, isolators, and cabinets for animal production science, serving medical research, pharmaceutical industry and industry; products based on laminar airflow and physical containment technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Noroit company profile →
Janvier Labs
HQ: France
Website
- Description: Provider of rodent research models and services, including immunodeficient models for studies in infectious diseases, immune system mechanisms, vaccine development, and cancer immunotherapy; humanized NXG-HIS mice with human-like immune systems for preclinical oncology and immunology; metabolic disease models; aged C57BL/6JRj mice and WISTAR rats; customized genetic model support; and SOPF/SPF colony management and logistics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Janvier Labs company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ALK
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ALK
2.2 - Growth funds investing in similar companies to ALK
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ALK
4.2 - Public trading comparable groups for ALK
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →